Qiagen and DiaSorin announced the launch of the Liaison LymeDetect assay for early detection of the Lyme Borreliosis infection. The test detects immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies and cellular immunity.
The test has a sensitivity of 74% and a specificity of 100% within 21 days from the first evidence of infection. It is available in markets accepting the CE Mark, and those that use the Liaison analyzer systems.
Qiagen is responsible for product development and manufacturing, and DiaSorin is handling its global commercialization.